Pharmacological resistance of PRL-secreting tumors is commonly defined as failure to normalize PRL levels and to achieve tumor size reduction of at least 50% upon treatment with the dopaminergic drug cabergoline (Peverelli et al. 2021). The gene discussed is PRL; the disease is neoplasm.